Urinary Dipeptidase 1 and Trefoil Factor 1 Are Promising Biomarkers for Early Diagnosis of Colorectal Cancer

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2024 Jun 5

PMID 38836911

Authors

Yusuke Okuda

Takaya Shimura

Yuichi Abe

Hiroyasu Iwasaki

Ruriko Nishigaki

Shigeki Fukusada

Naomi Sugimura

Mika Kitagawa

Tamaki Yamada

Ayumu Taguchi

Hiromi Kataoka

Affiliations

Soon will be listed here.

Abstract

Background: Currently utilized serum tumor markers and fecal immunochemical tests do not have sufficient diagnostic power for colorectal cancer (CRC) due to their low sensitivities. To establish non-invasive urinary protein biomarkers for early CRC diagnosis, we performed stepwise analyses employing urine samples from CRCs and healthy controls (HCs).

Methods: Among 474 urine samples, 363 age- and sex-matched participants (188 HCs, 175 stage 0-III CRCs) were randomly divided into discovery (16 HCs, 16 CRCs), training (110 HCs, 110 CRCs), and validation (62 HCs, 49 CRCs) cohorts.

Results: Of the 23 urinary protein candidates comprehensively identified from mass spectrometry in the discovery cohort, urinary levels of dipeptidase 1 (uDPEP1) and Trefoil factor1 (uTFF1) were the two most significant diagnostic biomarkers for CRC in both training and validation cohorts using enzyme-linked immunosorbent assays. A urinary biomarker panel comprising uDPEP1 and uTFF1 significantly distinguished CRCs from HCs, showing area under the curves of 0.825-0.956 for stage 0-III CRC and 0.792-0.852 for stage 0/I CRC. uDPEP1 and uTFF1 also significantly distinguished colorectal adenoma (CRA) patients from HCs, with uDPEP1 and uTFF1 increasing significantly in the order of HCs, CRA patients, and CRC patients. Moreover, expression levels of DPEP1 and TFF1 were also significantly higher in the serum and tumor tissues of CRC, compared to HCs and normal tissues, respectively.

Conclusions: This study established a promising and non-invasive urinary protein biomarker panel, which enables the early detection of CRC with high sensitivity.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Siegel R, Miller K, Sauer A, Fedewa S, Butterly L, Anderson J . Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3):145-164. DOI: 10.3322/caac.21601. View

Shaukat A, Mongin S, Geisser M, Lederle F, Bond J, Mandel J . Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013; 369(12):1106-14. DOI: 10.1056/NEJMoa1300720. View

Tao S, Haug U, Kuhn K, Brenner H . Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer. 2012; 106(8):1424-30. PMC: 3326680. DOI: 10.1038/bjc.2012.104. View

Xie Y, Gao Q, Cai G, Sun X, Sun X, Zou T . Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies. EBioMedicine. 2017; 25:32-40. PMC: 5704049. DOI: 10.1016/j.ebiom.2017.10.005. View

Thomas D, Fourkala E, Apostolidou S, Gunu R, Ryan A, Jacobs I . Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer. 2015; 113(2):268-74. PMC: 4506388. DOI: 10.1038/bjc.2015.202. View

Zhao M, Li M, Yang Y, Guo Z, Sun Y, Shao C . A comprehensive analysis and annotation of human normal urinary proteome. Sci Rep. 2017; 7(1):3024. PMC: 5465101. DOI: 10.1038/s41598-017-03226-6. View

Okuda Y, Shimura T, Iwasaki H, Fukusada S, Nishigaki R, Kitagawa M . Urinary microRNA biomarkers for detecting the presence of esophageal cancer. Sci Rep. 2021; 11(1):8508. PMC: 8058072. DOI: 10.1038/s41598-021-87925-1. View

Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T . Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila). 2015; 8(3):240-8. DOI: 10.1158/1940-6207.CAPR-14-0229. View

10.

Shimura T, Ebi M, Yamada T, Yamada T, Katano T, Nojiri Y . Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget. 2017; 8(17):29247-29257. PMC: 5438727. DOI: 10.18632/oncotarget.16453. View

11.

Iwasaki H, Shimura T, Yamada T, Okuda Y, Natsume M, Kitagawa M . A novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol. 2019; 54(12):1061-1069. DOI: 10.1007/s00535-019-01601-w. View

12.

Shimura T, Dayde D, Wang H, Okuda Y, Iwasaki H, Ebi M . Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer. 2020; 123(11):1656-1664. PMC: 7686371. DOI: 10.1038/s41416-020-01063-5. View

13.

Iwasaki H, Shimura T, Kitagawa M, Yamada T, Nishigaki R, Fukusada S . A Novel Urinary miRNA Biomarker for Early Detection of Colorectal Cancer. Cancers (Basel). 2022; 14(2). PMC: 8773893. DOI: 10.3390/cancers14020461. View

14.

Shimura T, Iwasaki H, Kitagawa M, Ebi M, Yamada T, Yamada T . Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer. Transl Oncol. 2019; 12(3):539-544. PMC: 6319190. DOI: 10.1016/j.tranon.2018.12.006. View

15.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005; 23(36):9067-72. DOI: 10.1200/JCO.2004.01.0454. View

16.

Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007; 18(6):805-35. DOI: 10.1097/EDE.0b013e3181577511. View

17.

Rappsilber J, Ishihama Y, Mann M . Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem. 2003; 75(3):663-70. DOI: 10.1021/ac026117i. View

18.

Xin G, Wang M, Jiao L, Xu G, Wang H . Protein-to-creatinine ratio in spot urine samples as a predictor of quantitation of proteinuria. Clin Chim Acta. 2004; 350(1-2):35-9. DOI: 10.1016/j.cccn.2004.06.019. View

19.

Ward D, Nyangoma S, Joy H, Hamilton E, Wei W, Tselepis C . Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. 2008; 6:19. PMC: 2440369. DOI: 10.1186/1477-5956-6-19. View

20.

Sun Y, Guo Z, Liu X, Yang L, Jing Z, Cai M . Noninvasive urinary protein signatures associated with colorectal cancer diagnosis and metastasis. Nat Commun. 2022; 13(1):2757. PMC: 9119985. DOI: 10.1038/s41467-022-30391-8. View